A61K 2039/507
Comprising a combination of two or more separate antibodies
Official title: {Comprising a combination of two or more separate antibodies}
A61K2039/507 (Comprising a combination of two or more separate antibodies) appears on 2,154 US grants and 5,021 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,154
- Published applications
- 5,021
- Assignees
- 1,393
- Inventors
- 8,608
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 1 |
| 2002 | 2 | 10 |
| 2003 | 0 | 11 |
| 2004 | 1 | 8 |
| 2005 | 2 | 13 |
| 2006 | 5 | 18 |
| 2007 | 2 | 36 |
| 2008 | 7 | 49 |
| 2009 | 10 | 61 |
| 2010 | 25 | 62 |
| 2011 | 26 | 114 |
| 2012 | 33 | 95 |
| 2013 | 59 | 121 |
| 2014 | 73 | 171 |
| 2015 | 77 | 197 |
| 2016 | 122 | 263 |
| 2017 | 112 | 299 |
| 2018 | 165 | 287 |
| 2019 | 149 | 359 |
| 2020 | 197 | 387 |
| 2021 | 197 | 433 |
| 2022 | 200 | 461 |
| 2023 | 182 | 413 |
| 2024 | 208 | 452 |
| 2025 | 178 | 424 |
| 2026 | 119 | 276 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Methods of identifying and evaluating cat allergy gene signatures in a subject by determining a stratified score based on gene expression29 Sep 2026US 12,747,287 B2Regeneron Pharmaceuticals, Inc.
- Anti-CCR8 antibodies for treating cancer29 Sep 2026US 12,747,296 B2Bristol-Myers Squibb Company
- Arginase 1 binders for inhibiting Arginase 1 activity15 Sep 2026US 12,735,506 B2Merck Sharp & Dohme Corp.
- Dosing for treatment with anti-CD20/anti-CD3 bispecific antibody8 Sep 2026US 12,729,243 B2Hoffmann-La Roche Inc.
- Methods and compositions for treating cancer8 Oct 2026US 2026/0308241 A1Chugai Seiyaku Kabushiki Kaisha
- Method of treating crohn's disease with a combination of antibodies to il-23 and tnf alpha8 Oct 2026US 2026/0308243 A1Janssen Biotech, Inc.
- Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an il-2 mutant and a cd80 extracellular domain8 Oct 2026US 2026/0308251 A1Gi Innovation, Inc.
- Combinations of anti-ctla-4 antibodies and anti-pd-1 antibodies and therapeutic uses thereof8 Oct 2026US 2026/0308256 A1AcroImmune Biopharma Co., Ltd.
- Methods of treating colorectal cancer using a combination of a ctla-4 inhibitor and a pd-1 inhibitor8 Oct 2026US 2026/0308257 A1Agenus Inc.
Most cited
By later US patents
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Anti-PD-L1 antibodies, compositions and articles of manufacture459US 8,217,149 B2Genentech, Inc. · 2012
- Immunotherapy of B-cell malignancies using anti-CD22 antibodies395US 6,306,393 B1Immunomedics, Inc. · 2001
- Methods of treating HIV infected subjects386US 6,905,680 B2Genetics Institute, Inc. · 2005
- Methods for treating HIV infected subjects339US 7,232,566 B2Genetics Institute, Inc. · 2007